INNOVIVA, INC. Inventory, Finished Goods, Net of Reserves
INNOVIVA, INC. (INVA) had Inventory, Finished Goods, Net of Reserves of $5.12 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2026-08-05
- 2026-06-30: Inventory, Finished Goods, Net of Reserves $5.12M.
- 2026-03-31: Inventory, Finished Goods, Net of Reserves $4.06M.
- 2025-12-31: Inventory, Finished Goods, Net of Reserves $4.97M.
- 2025-09-30: Inventory, Finished Goods, Net of Reserves $5.32M.
| Period end | Inventory, Finished Goods, Net of Reserves |
|---|---|
| 2026-06-30 | $5.12M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $4.06M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $4.97M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $5.32M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $4.29M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $3.44M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $2.08M 10-K · filed 2026-02-25 |
| 2024-09-30 | $4.31M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $4.34M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $7.72M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $13.81M 10-K · filed 2025-02-26 |
| 2023-09-30 | $18.43M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $14.12M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $21.36M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $25.09M 10-K/A · filed 2024-03-05 |
| 2022-09-30 | $10.92M 10-Q · filed 2022-11-09 |
| 2014-06-30 | $0.00 10-Q · filed 2014-08-07 |
| 2014-03-31 | $4.79M 10-Q · filed 2014-05-07 |
| 2013-12-31 | $4.91M 10-K · filed 2015-02-27 |
| 2013-09-30 | $1.35M 10-Q · filed 2013-11-01 |
| 2012-12-31 | $0.00 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |